BET inhibitors have effectively disrupted transcriptional programs driven by oncogenic transcription factors (TFs) (Kim et al, 2021; Shafran et al, 2021; Wyce et al, 2013) and inhibit tumor growth and metastasis (Delmore et al, 2011; Faivre et al, 2017; Shafran et al, 2021; Wyce et al, 2013; Xiang et al, 2018). The gene discussed is DNER; the disease is neoplasm.